Rep. Gilbert Ray Cisneros Jr. (D-CA) Sells BBIO Stock

Rep. Gilbert Ray Cisneros Jr., a Democrat from California's 31st District, sold shares of BridgeBio Pharma, Inc. (BBIO) on September 29, 2026. The transaction was valued between $1,001 and $15,000, according to a periodic transaction report filed under the STOCK Act on October 12, 2026.

What Changed in Gilbert Ray Cisneros Jr.'s BridgeBio Pharma Position

Cisneros's sale reflects a move away from his previous holdings in BridgeBio Pharma.

Other Institutional Activity in BridgeBio Pharma

Several other institutional investors have also been active in BridgeBio Pharma. Jupiter Topco LLC added 7,055,139 shares, bringing its total to 14,110,278 shares worth about $936.8 million. Farallon Capital Management LLC increased its holdings by 1,377,652 shares, totaling 10,743,063 shares valued at approximately $713.2 million. In contrast, Blackrock Inc. reduced its stake by 3,919,661 shares, ending with 10,287,156 shares worth about $683 million.

BridgeBio Pharma, Inc. Stock Down 1.4%

As of October 16, 2026, BridgeBio Pharma shares traded recently around $66.20, which is below both its 50-day moving average of $73.27 and its 200-day average of $73.13. The stock is also down about 29.1% from its 52-week high of $93.42, but remains above its 52-week low of $52.75.

Recent Earnings

BridgeBio Pharma reported trailing twelve-month revenue of $713.1 million, reflecting a 120.4% year-over-year growth. However, the company has not turned a profit, showing a negative EPS of $3.56. The next earnings report is scheduled for October 28, 2026.

Insider Buying and Selling at BridgeBio Pharma, Inc.

Several insiders have sold shares recently. Andrea Ellis, a Director, sold 17,167 shares on July 9, 2026, valued at approximately $1.44 million. Additionally, Neil Kumar, the CEO, sold 10,000 shares on September 17, 2026, for about $690,847. These transactions occurred before Cisneros's sale.

Analysts Set New Price Targets

Analysts maintain a strong buy consensus on BridgeBio Pharma. On August 12, 2026, Truist Securities and Canaccord Genuity both maintained buy ratings with price targets of $107.00 and $106.00, respectively. Mizuho also holds an outperform rating with a target of $110.00 as of September 1, 2026. The mean price target among analysts is $108.27, indicating potential upside from recent trading levels.

About BridgeBio Pharma

BridgeBio Pharma, Inc. is a biopharmaceutical company focused on discovering and developing medicines for patients with genetic diseases. The company's innovative approach aims to address significant unmet medical needs in the healthcare sector, making it a key player in biotechnology.

Bottom Line

Looking ahead, investors may watch for BridgeBio's upcoming earnings report on October 28, 2026, as well as any further disclosures related to insider trading and institutional investments. Cisneros's recent sale adds to his history of stock transactions, including previous sales of Workday and W. R. Berkley shares earlier this year.